Literature DB >> 19758299

Variability in calcium, phosphorus, and parathyroid hormone in patients on hemodialysis.

Helena Levitt1, Kenneth G Smith, Mitchell H Rosner.   

Abstract

Calcium, phosphorus, and parathyroid hormone (PTH) levels are routinely measured in patients undergoing chronic hemodialysis. Medications, diet, and dialytic therapies are modified based upon these lab values to achieve specific goal values in the hope of improving outcomes. However, the variability of these values in patients undergoing chronic hemodialysis has only been rarely studied. We prospectively investigated the variability of these measures in 35 patients undergoing chronic hemodialysis as well as the impact of this variability on clinical decision-making in a prospective manner over a month. There is significant session-to-session variability in phosphorus and PTH values (mean coefficient of variations [CV] of 0.19 and 0.31, respectively). Calcium variability is much lower (mean CV of 0.05). Not surprisingly, the CV for all values is increased during the long interdialytic interval. The impact of this variability on clinical decision-making was analyzed. The variability in calcium, phosphorus, and PTH values would lead to a different clinical decision in 23.6%, 41.2%, and 39.7% of different session lab values. We also investigated the variability of these lab measures over a year in these patients and found that the session-to-session variability was very similar to the month-to-month variability. The high degree of variability of these parameters has important implications for clinical decision-making and for implementation of pay-for-performance measures.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19758299     DOI: 10.1111/j.1542-4758.2009.00393.x

Source DB:  PubMed          Journal:  Hemodial Int        ISSN: 1492-7535            Impact factor:   1.812


  5 in total

1.  Variability in measures of mineral metabolism in children on hemodialysis: impact on clinical decision-making.

Authors:  Aadil Kakajiwala; Thomas O Jemielita; Lawrence Copelovitch; Mary B Leonard; Susan L Furth; Amy York; Maryjane Benton; Andrew N Hoofnagle; Kimberly Windt; Karen Merrigan; April Lederman; Michelle R Denburg
Journal:  Pediatr Nephrol       Date:  2017-06-30       Impact factor: 3.714

Review 2.  Monitoring of inflammation in patients on dialysis: forewarned is forearmed.

Authors:  Christiaan L Meuwese; Peter Stenvinkel; Friedo W Dekker; Juan J Carrero
Journal:  Nat Rev Nephrol       Date:  2011-03       Impact factor: 28.314

3.  Single FGF-23 measurement and time-averaged plasma phosphate levels in hemodialysis patients.

Authors:  Sarah Seiler; Gaetano Lucisano; Philipp Ege; Lisa H Fell; Kyrill S Rogacev; Anne Lerner-Gräber; Matthias Klingele; Matthias Ziegler; Danilo Fliser; Gunnar H Heine
Journal:  Clin J Am Soc Nephrol       Date:  2013-07-11       Impact factor: 8.237

4.  Trajectories of CKD-MBD biochemical parameters over a 2-year period following diagnosis of secondary hyperparathyroidism: a pharmacoepidemiological study.

Authors:  Pierre Filipozzi; Carole Ayav; Willy Ngueyon Sime; Emmanuelle Laurain; Michèle Kessler; Laurent Brunaud; Luc Frimat
Journal:  BMJ Open       Date:  2017-03-27       Impact factor: 2.692

5.  Metabolic and volume status evaluation of hemodialysis patients with and without residual renal function in the long interdialytic interval.

Authors:  Lenina Ludimila Sampaio de Almeida; Luís Henrique Bezerra Cavalanti Sette; Fernando Luiz Affonso Fonseca; Leila Silveira Vieira da Silva Bezerra; Francisco Hélio Oliveira Júnior; Ronaldo Roberto Bérgamo
Journal:  J Bras Nefrol       Date:  2019 Oct-Dec
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.